Multiple biomarkers risk score for accurately predicting the long-term prognosis of patients with acute coronary syndrome.
10.26599/1671-5411.2025.07.001
- Author:
Zhi-Yong ZHANG
1
;
Xin-Yu WANG
1
;
Cong-Cong HOU
2
;
Hong-Bin LIU
3
;
Lyu LYU
2
;
Mu-Lei CHEN
1
;
Xiao-Rong XU
1
;
Feng JIANG
1
;
Long LI
1
;
Wei-Ming LI
1
;
Kui-Bao LI
1
;
Juan WANG
1
Author Information
1. Heart-center of Beijing Chao-Yang Hospital, Capital Medical University, Beijing Key Laboratory of Hypertension, Beijing, China.
2. Department of Cardiology, Chui Yang Liu Hospital, Tsinghua University, Beijing, China.
3. Department of Cardiology, the Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
- Publication Type:Journal Article
- From:
Journal of Geriatric Cardiology
2025;22(7):656-667
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Biomarkers-based prediction of long-term risk of acute coronary syndrome (ACS) is scarce. We aim to develop a risk score integrating clinical routine information (C) and plasma biomarkers (B) for predicting long-term risk of ACS patients.
METHODS:We included 2729 ACS patients from the OCEA (Observation of cardiovascular events in ACS patients). The earlier admitted 1910 patients were enrolled as development cohort; and the subsequently admitted 819 subjects were treated as validation cohort. We investigated 10-year risk of cardiovascular (CV) death, myocardial infarction (MI) and all cause death in these patients. Potential variables contributing to risk of clinical events were assessed using Cox regression models and a score was derived using main part of these variables.
RESULTS:During 16,110 person-years of follow-up, there were 238 CV death/MI in the development cohort. The 7 most important predictors including in the final model were NT-proBNP, D-dimer, GDF-15, peripheral artery disease (PAD), Fibrinogen, ST-segment elevated MI (STEMI), left ventricular ejection fraction (LVEF), termed as CB-ACS score. C-index of the score for predication of cardiovascular events was 0.79 (95% CI: 0.76-0.82) in development cohort and 0.77 (95% CI: 0.76-0.78) in the validation cohort (5832 person-years of follow-up), which outperformed GRACE 2.0 and ABC-ACS risk score. The CB-ACS score was also well calibrated in development and validation cohort (Greenwood-Nam-D'Agostino: P = 0.70 and P = 0.07, respectively).
CONCLUSIONS:CB-ACS risk score provides a useful tool for long-term prediction of CV events in patients with ACS. This model outperforms GRACE 2.0 and ABC-ACS ischemic risk score.
